Shopping Cart
Remove All
Your shopping cart is currently empty
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. It exhibits antiproliferative effects on MCF7, HCT116, and EKVX cancer cell lines with IC50s of 3.36 μM, 1.40 μM, and 3.49 μM, respectively. Additionally, Multi-kinase-IN-6 induces cell cycle arrest at the G1/S and G1 phases in MCF7 and HCT116 cells, respectively, and effectively triggers apoptosis [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. It exhibits antiproliferative effects on MCF7, HCT116, and EKVX cancer cell lines with IC50s of 3.36 μM, 1.40 μM, and 3.49 μM, respectively. Additionally, Multi-kinase-IN-6 induces cell cycle arrest at the G1/S and G1 phases in MCF7 and HCT116 cells, respectively, and effectively triggers apoptosis [1]. |
| Targets&IC50 | TrkA:0.33 μM, Chk1:0.15 μM, FLT3:0.34 μM, c-Kit:0.05 μM, PIM1:0.42 μM, CK2:0.09 μM, EGFR:0.1 μM, CDK2:0.71 μM, ROS1:0.75 μM, RET:0.53 μM, ALK2:0.03 μM |
| In vitro | MK2-IN-5 at concentrations of 5-10 μM for 2 hours inhibits the expression of connective tissue growth factor and type I collagen induced by TGF-b1 in human scar keloid fibroblasts [3]. |
| In vivo | MK2-IN-5 (2 mg/kg, intraperitoneal injection, single dose) reduces the phosphorylation of HSP25 in ventilator-induced lung injury models [2]. |
| Animal Research | s |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.